A bivalent Lassa virus mRNA vaccine protects guinea pigs from lethal infection with Lassa virus

In the dense forests and rural villages of West Africa, a silent and deadly threat persists: Lassa fever. Caused by the Lassa virus, this illness brings high fevers, severe bleeding, and often death, claiming thousands of lives annually. For decades, the medical community has lacked a licensed vaccine to stop it, leaving communities vulnerable and treatment options limited to a drug that is only partially effective and carries heavy side effects. The virus is tricky; it hides inside the body and evolves rapidly, making it difficult to target with traditional vaccines that rely on training the immune system to recognize a specific surface shape. Scientists have long known that the body's cellular defense force, the T-cells, plays a critical role in fighting off this infection, yet creating a vaccine that reliably triggers these cells without causing harm has remained a formidable challenge.

A team of researchers has now taken a significant step forward by testing a new type of vaccine design that uses genetic instructions to train the immune system. Instead of injecting a weakened virus or a piece of the virus itself, this approach delivers a set of molecular blueprints—messenger RNA—encased in tiny, protective fat bubbles. Once inside the body, these instructions tell the cells to build specific viral proteins, which the immune system then learns to recognize and attack. In this study, the scientists focused on two key proteins from the Lassa virus: one that sits on the virus's surface and another that forms its internal core. They wanted to see if teaching the body to recognize both of these parts would offer better protection than teaching it to recognize just one.

The researchers began their work in a controlled laboratory setting using mice, a standard model for testing how well a vaccine might work before moving to more complex animals. They created two separate vaccine doses: one containing instructions for the surface protein and another for the internal core protein. They also created a combined, or "bivalent," dose that contained instructions for both proteins at the same time. When they challenged the vaccinated mice with a lethal dose of a virus engineered to mimic the dangerous effects of Lassa fever, the results were striking. The mice that received the single-protein vaccines survived at high rates, but not perfectly; some still fell ill. However, the mice that received the combined vaccine were completely protected, surviving the lethal challenge without any signs of sickness. This happened even when the researchers used a much smaller amount of the vaccine material, suggesting that mixing the two instructions together makes the immune response more efficient and powerful.

A closer look at the immune system's reaction revealed why this combination worked so well. The researchers found that the vaccines did not produce the usual flood of neutralizing antibodies that many vaccines rely on to block a virus. Instead, the protection came almost entirely from the T-cells, the immune system's specialized soldiers that hunt down and destroy infected cells. The combined vaccine successfully trained the mice to produce a robust army of these cells, specifically targeting the unique signatures of both the surface and internal proteins. By identifying the exact parts of these proteins that the T-cells recognized, the team confirmed that the vaccine was teaching the immune system to spot the virus from multiple angles, creating a safety net that a single-target vaccine could not provide.

To ensure these findings were not just a quirk of the mouse model, the team moved to a more rigorous test using guinea pigs, which are known to be highly susceptible to the actual Lassa virus and develop symptoms very similar to humans. They vaccinated these animals with the combined formula and then exposed them to a real, lethal dose of the virus. The results mirrored the mouse experiments perfectly. Every guinea pig that received the bivalent vaccine survived the infection, showing no weight loss or fever, while the unvaccinated animals succumbed to the disease. Remarkably, this complete protection was achieved even with a very low dose of the vaccine material. Just as in the mice, the vaccinated guinea pigs did not produce strong neutralizing antibodies, reinforcing the conclusion that the cellular defense, driven by the dual-protein approach, was the key to survival.

The study also addressed a common concern in vaccine development: whether the virus's ability to change its genetic code would render the vaccine useless. The researchers examined the genetic sequences of the virus from different regions and found that the specific parts of the proteins targeted by the T-cells remained largely unchanged across different strains. This suggests that the vaccine's ability to train the immune system to recognize these stable, unchanging regions could offer broad protection against various forms of the virus circulating in the wild. While the research is still in the preclinical stage and has not yet been tested in humans, the findings provide a compelling reason to pursue this dual-protein strategy. By combining the surface and internal instructions, the vaccine appears to offer a more robust and efficient shield, potentially allowing for lower doses and greater protection in the face of a virus that has long evaded effective prevention.